# US 10,369,266 B2 · Multipart fluid system and a system for citrate anticoagulation in an extracorporeal blood circuit

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,266 B2
- Document ID: US10369266B2
- Status: Granted
- Kind: B2
- Application number: 14/779,836
- Filed: 2014-04-30
- Published: 2016-04-21
- Granted: 2019-08-06
- Earliest claimed: 2013-04-30
- Assignees: Gambro Lundia AB
- Applicants: Gambro Lundia AB
- Inventors: Petra Åhl; Gabriela Godaly; Jan Sternby; Anders Wieslander
- Web page: https://patentgrep.com/patent/US10369266B2

## CPC

- A61M 1/3672: {Means preventing coagulation}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0026: {Blood substitute; Oxygen transporting formulations; Plasma extender}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/225: Polycarboxylic acids
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/10: Carbonates; Bicarbonates
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 33/42: Phosphorus; Compounds thereof
- A61M 1/1654: {Dialysates therefor}
- A61M 1/1672: {using membrane filters, e.g. for sterilising the dialysate}
- A61M 1/342: {Adding solutions to the blood, e.g. substitution solutions (for preventing coagulation A61M1/3672)}
- A61M 1/3434: {with pre-dilution and post-dilution}
- A61M 1/3437: {downstream of the filter, e.g. post-dilution with filtrate}
- A61M 1/3441: {Substitution rate control as a function of the ultrafiltration rate}
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61K 47/02: Inorganic compounds
- A61M 1/3675: {Deactivation}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns a multipart fluid system for dialysis therapy, wherein the multipart fluid system comprises an anticoagulation fluid and at least one treatment fluid from the group consisting of dialysis fluid and infusion fluids. According to the invention the anticoagulation fluid comprises 15-40 mM citrate; and the at least one treatment fluid comprises 1.5-8 mM citrate and ≥10 mM bicarbonate. The present invention further concerns a system for citrate anticoagulation in an extracorporeal blood circuit.

## Claims

### Claim 1

A multipart fluid system for dialysis therapy, the multipart fluid system comprising:
an anticoagulation fluid; and
at least one treatment fluid from the group consisting of dialysis fluid and infusion fluids, wherein the anticoagulation fluid comprises 15-40 mM citrate, the at least one treatment fluid comprises 1.5-8 mM citrate and >10 mM bicarbonate, and wherein a level of the bicarbonate in the at least one treatment fluid is selected from a set of bicarbonate levels that satisfy a relationship in which the level of the bicarbonate is decreased with increased citrate levels in the anticoagulation fluid.

### Claim 2 (depends on 1)

The multipart fluid system according to claim 1, wherein said anticoagulation fluid comprises 18-40 mM citrate.

### Claim 3 (depends on 1)

The multipart fluid system according to claim 1, wherein said at least one treatment fluid comprises 10-30 mM bicarbonate.

### Claim 4 (depends on 1)

The multipart fluid system according to claim 1, wherein said at least one treatment fluid comprises 1-5 mM total calcium.

### Claim 5 (depends on 1)

The multipart fluid system according to claim 1, wherein said at least one treatment fluid comprises 2.0-7.0 mM citrate and 1.5-2.4 mM total calcium.

### Claim 6 (depends on 1)

The multipart fluid system according to claim 1, wherein said at least one treatment fluid comprises 3.5-5.5 mM citrate and 1.5-2.4 mM total calcium.

### Claim 7 (depends on 1)

The multipart fluid system according to claim 1, wherein said at least one treatment fluid further comprises 0-1.5 mM magnesium, 0-5.0 mM potassium, 0-11 mM glucose, 130-150 mM sodium.

### Claim 8 (depends on 1)

The multipart fluid system according to claim 1, wherein said at least one treatment fluid further comprises 0.1-2.0 mM phosphate.

### Claim 9 (depends on 1)

The multipart fluid system according to claim 1, wherein said anticoagulation fluid comprises 1.5-4 mM total calcium.

### Claim 10 (depends on 1)

The multipart fluid system according to claim 1, wherein said anticoagulation fluid further comprises 0-1.5 mM magnesium, 0-5.0 mM potassium, 0-11 mM glucose, 130-150 mM sodium.

### Claim 11 (depends on 1)

The multipart fluid system according to claim 1, wherein said anticoagulation fluid further comprises 0.1-2.0 mM phosphate.

### Claim 12 (depends on 1)

The multipart fluid system according to claim 1, wherein the level of the bicarbonate is decreased from 20 mM to 12 mM with increased citrate levels from 18 mM to 40 mM in the anticoagulation fluid.